Skip to main content
Erschienen in: Current Treatment Options in Oncology 5-6/2009

01.12.2009 | Breast Cancer

Maintaining Fertility in Young Women with Breast Cancer

verfasst von: Melissa C. Hulvat, MD, Jacqueline S. Jeruss, MD, PhD

Erschienen in: Current Treatment Options in Oncology | Ausgabe 5-6/2009

Einloggen, um Zugang zu erhalten

Opinion statement

Breast cancer effects nearly 200,000 American women each year, with 9% of these women still in their childbearing years. For this subset of future survivors, the issue of fertility may be a significant quality-of-life concern. Both the causes and treatments for infertility in young breast cancer patients must be thoroughly understood by the multidisciplinary team caring for these women in order for the caregivers to be effective advocates for their patients. Radiation, cytotoxic chemotherapy, and hormonal therapy all effect ovarian function to greater or lesser degrees, with the incidence of permanent post-treatment amenorrhea following systemic treatment for breast cancer in women age 50 or younger estimated as between 33% and 76%. The science of fertility preservation continues to experience significant advances in terms of the success of oocyte, embryo, and ovarian tissue preservation, and it is crucial that physicians and patients are aware of the available fertility preservation options. The optimal time to address the possibility of treatment-related infertility and strategies to combat this with younger patients is prior to treatment, rather than after cancer therapy has begun, and a full knowledge of the available technologies is a prerequisite for an informed discussion. Causes of ovarian suppression and options for treatment, including consideration of preimplantation genetic diagnosis and alternative parenting approaches are also discussed to assist the clinician caring for young patients with cancer.
Literatur
1.
Zurück zum Zitat Bines J, Oleske DM, Cobleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996,14(5):1718–1729.PubMed Bines J, Oleske DM, Cobleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996,14(5):1718–1729.PubMed
4.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007, 57(1):43–66.CrossRefPubMed Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007, 57(1):43–66.CrossRefPubMed
5.
Zurück zum Zitat ACS. Breast Cancer Facts & Figures 2007–2008. Report. Atlanta, GA: American Cancer Society, Inc.; 2008 ACS. Breast Cancer Facts & Figures 2007–2008. Report. Atlanta, GA: American Cancer Society, Inc.; 2008
6.
Zurück zum Zitat Lee SJ, Schover LR, Partridge AH, et al.: American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006, 24(18):2917–2931.CrossRefPubMed Lee SJ, Schover LR, Partridge AH, et al.: American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006, 24(18):2917–2931.CrossRefPubMed
7.
Zurück zum Zitat Partridge AH, Gelber S, Peppercorn J, et al.: Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004, 22(20):4174–4183.CrossRefPubMed Partridge AH, Gelber S, Peppercorn J, et al.: Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004, 22(20):4174–4183.CrossRefPubMed
8.
Zurück zum Zitat Falcone T, Attaran M, Bedaiwy MA, Goldberg JM: Ovarian function preservation in the cancer patient. Fertil Steril 2004, 81(2):243–257.CrossRefPubMed Falcone T, Attaran M, Bedaiwy MA, Goldberg JM: Ovarian function preservation in the cancer patient. Fertil Steril 2004, 81(2):243–257.CrossRefPubMed
9.
Zurück zum Zitat Meirow D, Nugent D: The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001, 7(6):535–543.CrossRefPubMed Meirow D, Nugent D: The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001, 7(6):535–543.CrossRefPubMed
10.
Zurück zum Zitat Maltaris T, Seufert R, Fischl F, et al.: The effect of cancer treatment on female fertility and strategies for preserving fertility. Eur J Obstet Gynecol Reprod Biol 2007, 130(2):148–155.CrossRefPubMed Maltaris T, Seufert R, Fischl F, et al.: The effect of cancer treatment on female fertility and strategies for preserving fertility. Eur J Obstet Gynecol Reprod Biol 2007, 130(2):148–155.CrossRefPubMed
11.
Zurück zum Zitat Wallace WH, Thomson AB, Saran F, Kelsey TW: Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys 2005, 62(3):738–744.PubMed Wallace WH, Thomson AB, Saran F, Kelsey TW: Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys 2005, 62(3):738–744.PubMed
12.
Zurück zum Zitat Critchley HO, Wallace WH, et al.: Impact of cancer treatment on uterine function. J Natl Cancer Inst Monogr 2005, 34:64–68.CrossRefPubMed Critchley HO, Wallace WH, et al.: Impact of cancer treatment on uterine function. J Natl Cancer Inst Monogr 2005, 34:64–68.CrossRefPubMed
13.
Zurück zum Zitat Fenig E, Mishaeli M, Kalish Y, Lishner M: Pregnancy and radiation. Cancer Treat Rev 2001, 27(1):1–7.CrossRefPubMed Fenig E, Mishaeli M, Kalish Y, Lishner M: Pregnancy and radiation. Cancer Treat Rev 2001, 27(1):1–7.CrossRefPubMed
14.
Zurück zum Zitat Mazonakis M, Varveris H, Damilakis J, Theoharopoulos N, Gourtsoyiannis N: Radiation dose to conceptus resulting from tangential breast irradiation. Int J Radiat Oncol Biol Phys 2003, 55(2):386–391.PubMed Mazonakis M, Varveris H, Damilakis J, Theoharopoulos N, Gourtsoyiannis N: Radiation dose to conceptus resulting from tangential breast irradiation. Int J Radiat Oncol Biol Phys 2003, 55(2):386–391.PubMed
15.
Zurück zum Zitat Antypas C, Sandilos P, Kouvaris J, et al.: Fetal dose evaluation during breast cancer radiotherapy. Int J Radiat Oncol Biol Phys 1998, 40(4):995–999.CrossRefPubMed Antypas C, Sandilos P, Kouvaris J, et al.: Fetal dose evaluation during breast cancer radiotherapy. Int J Radiat Oncol Biol Phys 1998, 40(4):995–999.CrossRefPubMed
16.
Zurück zum Zitat Lutchman Singh K, Muttukrishna S, Stein RC, et al.: Predictors of ovarian reserve in young women with breast cancer. Br J Cancer 2007, 96(12):1808–1816.CrossRefPubMed Lutchman Singh K, Muttukrishna S, Stein RC, et al.: Predictors of ovarian reserve in young women with breast cancer. Br J Cancer 2007, 96(12):1808–1816.CrossRefPubMed
17.
Zurück zum Zitat Visser JA, Themmen AP: Anti-Mullerian hormone and folliculogenesis. Mol Cell Endocrinol 2005, 234(1–2):81–86.CrossRefPubMed Visser JA, Themmen AP: Anti-Mullerian hormone and folliculogenesis. Mol Cell Endocrinol 2005, 234(1–2):81–86.CrossRefPubMed
18.
Zurück zum Zitat Anders C, Marcom PK, Peterson B, et al.: A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest 2008, 26(3):286–295.CrossRefPubMed Anders C, Marcom PK, Peterson B, et al.: A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest 2008, 26(3):286–295.CrossRefPubMed
19.
Zurück zum Zitat Sonmezer M, Oktay K: Fertility preservation in female patients. Hum Reprod Update 2004, 10(3):251–266.CrossRefPubMed Sonmezer M, Oktay K: Fertility preservation in female patients. Hum Reprod Update 2004, 10(3):251–266.CrossRefPubMed
20.
Zurück zum Zitat Petrek JA, Naughton MJ, Case LD, et al.: Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006, 24(7):1045–1051.CrossRefPubMed Petrek JA, Naughton MJ, Case LD, et al.: Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006, 24(7):1045–1051.CrossRefPubMed
21.••
Zurück zum Zitat Maltaris T, Weigel M, Mueller A, et al.: Cancer and fertility preservation: fertility preservation in breast cancer patients. Breast Cancer Res 2008, 10(2):206.CrossRefPubMed Maltaris T, Weigel M, Mueller A, et al.: Cancer and fertility preservation: fertility preservation in breast cancer patients. Breast Cancer Res 2008, 10(2):206.CrossRefPubMed
22.
Zurück zum Zitat Halakivi-Clarke L, Cho E, Onojafe I, Liao DJ, Clarke R: Maternal exposure to tamoxifen during pregnancy increases carcinogen-induced mammary tumorigenesis among female rat offspring. Clin Cancer Res 2000, 6(1):305–308.PubMed Halakivi-Clarke L, Cho E, Onojafe I, Liao DJ, Clarke R: Maternal exposure to tamoxifen during pregnancy increases carcinogen-induced mammary tumorigenesis among female rat offspring. Clin Cancer Res 2000, 6(1):305–308.PubMed
24.
Zurück zum Zitat Gradishar WJ, Hellmund R: A rationale for the reinitiation of adjuvant tamoxifen therapy in women receiving fewer than 5 years of therapy. Clin Breast Cancer 2002, 2(4):282–286.CrossRefPubMed Gradishar WJ, Hellmund R: A rationale for the reinitiation of adjuvant tamoxifen therapy in women receiving fewer than 5 years of therapy. Clin Breast Cancer 2002, 2(4):282–286.CrossRefPubMed
25.
Zurück zum Zitat Arnon J, Meirow D, Lewis-Roness H, Ornoy A: Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update 2001,7(4):394–403.CrossRefPubMed Arnon J, Meirow D, Lewis-Roness H, Ornoy A: Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update 2001,7(4):394–403.CrossRefPubMed
26.
Zurück zum Zitat Partridge AH, Ruddy KJ: Fertility and adjuvant treatment in young women with breast cancer. The Breast 2007, 16(Suppl 2):175–181.CrossRef Partridge AH, Ruddy KJ: Fertility and adjuvant treatment in young women with breast cancer. The Breast 2007, 16(Suppl 2):175–181.CrossRef
27.••
Zurück zum Zitat Lobo RA: Potential options for preservation of fertility in women. N Engl J Med 2005, 353(1):64–73.CrossRefPubMed Lobo RA: Potential options for preservation of fertility in women. N Engl J Med 2005, 353(1):64–73.CrossRefPubMed
28.
Zurück zum Zitat Recchia F, Saggio G, Amiconi G, et al.: Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006, 106(3):514–523.CrossRefPubMed Recchia F, Saggio G, Amiconi G, et al.: Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006, 106(3):514–523.CrossRefPubMed
29.
Zurück zum Zitat Ambrosone GB, Barlow W, Yeh I-T, et al.: Pharmacogenetics and breast cancer treatment outcomes: results on oxidative stress-related genotypes (MPO, MnSOD) from a southwest oncology intergroup trial (INT-0102). Cancer 2006, 100:S18. Ambrosone GB, Barlow W, Yeh I-T, et al.: Pharmacogenetics and breast cancer treatment outcomes: results on oxidative stress-related genotypes (MPO, MnSOD) from a southwest oncology intergroup trial (INT-0102). Cancer 2006, 100:S18.
30.
Zurück zum Zitat Urruticoechea A, Arnedos M, Walsh G, Dowsett M, Smith IE: Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Res Treat 2008, 110(3):411–416.CrossRefPubMed Urruticoechea A, Arnedos M, Walsh G, Dowsett M, Smith IE: Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Res Treat 2008, 110(3):411–416.CrossRefPubMed
31.
Zurück zum Zitat Cahill DJ, Wardle PG, Harlow CR, Hunt LP, Hull MG: Expected contribution to serum oestradiol from individual ovarian follicles in unstimulated cycles. Hum Reprod 2000, 15(9):1909–1912.CrossRefPubMed Cahill DJ, Wardle PG, Harlow CR, Hunt LP, Hull MG: Expected contribution to serum oestradiol from individual ovarian follicles in unstimulated cycles. Hum Reprod 2000, 15(9):1909–1912.CrossRefPubMed
32.
Zurück zum Zitat Gupta PB, Kuperwasser C: Contributions of estrogen to ER-negative breast tumor growth. J Steroid Biochem Mol Biol 2006, 102(1–5):71–78.CrossRefPubMed Gupta PB, Kuperwasser C: Contributions of estrogen to ER-negative breast tumor growth. J Steroid Biochem Mol Biol 2006, 102(1–5):71–78.CrossRefPubMed
33.
Zurück zum Zitat Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z: Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 2003, 18(1):90–95.CrossRefPubMed Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z: Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 2003, 18(1):90–95.CrossRefPubMed
34.
Zurück zum Zitat Oktay K: Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. J Clin Oncol 2005, 23(16):3858–3859.CrossRefPubMed Oktay K: Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. J Clin Oncol 2005, 23(16):3858–3859.CrossRefPubMed
35.
Zurück zum Zitat Azim AA, Costantini-Ferrando M, Oktay K: Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 2008, 26(16):2630–2635.CrossRefPubMed Azim AA, Costantini-Ferrando M, Oktay K: Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 2008, 26(16):2630–2635.CrossRefPubMed
36.
Zurück zum Zitat Madrigrano A, Westphal L, Wapnir I: Egg retrieval with cryopreservation does not delay breast cancer treatment. Am J Surg 2007, 194(4):477–481.CrossRefPubMed Madrigrano A, Westphal L, Wapnir I: Egg retrieval with cryopreservation does not delay breast cancer treatment. Am J Surg 2007, 194(4):477–481.CrossRefPubMed
37.
Zurück zum Zitat Stachecki JJ, Cohen J: An overview of oocyte cryopreservation. Reprod Biomed Online 2004, 9(2):152–163.PubMedCrossRef Stachecki JJ, Cohen J: An overview of oocyte cryopreservation. Reprod Biomed Online 2004, 9(2):152–163.PubMedCrossRef
38.
Zurück zum Zitat Tao T, Del Valle A: Human oocyte and ovarian tissue cryopreservation and its application. J Assist Reprod Genet 2008, 25(7):287–296.CrossRefPubMed Tao T, Del Valle A: Human oocyte and ovarian tissue cryopreservation and its application. J Assist Reprod Genet 2008, 25(7):287–296.CrossRefPubMed
39.
Zurück zum Zitat Porcu E, Bazzocchi A, Notarangelo L, Paradisi R, Landolfo C, Venturoli S: Human oocyte cryopreservation in infertility and oncology. Curr Opin Endocrinol Diabetes Obes 2008, 15(6):529–535.PubMed Porcu E, Bazzocchi A, Notarangelo L, Paradisi R, Landolfo C, Venturoli S: Human oocyte cryopreservation in infertility and oncology. Curr Opin Endocrinol Diabetes Obes 2008, 15(6):529–535.PubMed
40.
Zurück zum Zitat Backhus LE, Kondapalli LA, Chang RJ, Coutifaris C, Kazer R, Woodruff TK: Oncofertility consortium consensus statement: guidelines for ovarian tissue cryopreservation. Cancer Treat Res 2007, 138:235–239.CrossRefPubMed Backhus LE, Kondapalli LA, Chang RJ, Coutifaris C, Kazer R, Woodruff TK: Oncofertility consortium consensus statement: guidelines for ovarian tissue cryopreservation. Cancer Treat Res 2007, 138:235–239.CrossRefPubMed
41.
Zurück zum Zitat Sanchez M, Novella-Maestre E, Teruel J, Ortiz E, Pellicer A: The Valencia programme for fertility preservation. Clin Transl Oncol 2008, 10(7):433–438.CrossRefPubMed Sanchez M, Novella-Maestre E, Teruel J, Ortiz E, Pellicer A: The Valencia programme for fertility preservation. Clin Transl Oncol 2008, 10(7):433–438.CrossRefPubMed
42.
Zurück zum Zitat Demeestere I, Simon P, Emiliani S, Delbaere A, Englert Y: Fertility preservation: successful transplantation of cryopreserved ovarian tissue in a young patient previously treated for Hodgkin’s disease. Oncologist 2007, 12(12):1437–1442.CrossRefPubMed Demeestere I, Simon P, Emiliani S, Delbaere A, Englert Y: Fertility preservation: successful transplantation of cryopreserved ovarian tissue in a young patient previously treated for Hodgkin’s disease. Oncologist 2007, 12(12):1437–1442.CrossRefPubMed
43.
Zurück zum Zitat Donnez J, Dolmans MM, Demylle D, et al.: Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004, 364(9443):1405–1410.CrossRefPubMed Donnez J, Dolmans MM, Demylle D, et al.: Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004, 364(9443):1405–1410.CrossRefPubMed
44.
Zurück zum Zitat Meirow D, Levron J, Eldar-Geva T, et al.: Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med 2005, 353(3):318–321.CrossRefPubMed Meirow D, Levron J, Eldar-Geva T, et al.: Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med 2005, 353(3):318–321.CrossRefPubMed
45.
Zurück zum Zitat Woodruff TK, Shea LD: The role of the extracellular matrix in ovarian follicle development. Reprod Sci 2007, 14(8 Suppl):6–10.CrossRefPubMed Woodruff TK, Shea LD: The role of the extracellular matrix in ovarian follicle development. Reprod Sci 2007, 14(8 Suppl):6–10.CrossRefPubMed
46.•
Zurück zum Zitat Xu M, Woodruff TK, Shea LD: Bioengineering and the ovarian follicle. Cancer Treat Res 2007, 138:75–82.CrossRefPubMed Xu M, Woodruff TK, Shea LD: Bioengineering and the ovarian follicle. Cancer Treat Res 2007, 138:75–82.CrossRefPubMed
47.
Zurück zum Zitat Telfer EE, McLaughlin M, Ding C, Thong KJ: A two-step serum-free culture system supports development of human oocytes from primordial follicles in the presence of activin. Hum Reprod 2008, 23(5):1151–1158.CrossRefPubMed Telfer EE, McLaughlin M, Ding C, Thong KJ: A two-step serum-free culture system supports development of human oocytes from primordial follicles in the presence of activin. Hum Reprod 2008, 23(5):1151–1158.CrossRefPubMed
48.
Zurück zum Zitat Xu M, Kreeger PK, Shea LD, Woodruff TK: Tissue-engineered follicles produce live, fertile offspring. Tissue Eng 2006, 12(10):2739–2746.CrossRefPubMed Xu M, Kreeger PK, Shea LD, Woodruff TK: Tissue-engineered follicles produce live, fertile offspring. Tissue Eng 2006, 12(10):2739–2746.CrossRefPubMed
49.
Zurück zum Zitat Verlinsky Y, Cohen J, Munne S, et al.: Over a decade of experience with preimplantation genetic diagnosis: a multicenter report. Fertil Steril 2004, 82(2):292–294.CrossRefPubMed Verlinsky Y, Cohen J, Munne S, et al.: Over a decade of experience with preimplantation genetic diagnosis: a multicenter report. Fertil Steril 2004, 82(2):292–294.CrossRefPubMed
50.
Zurück zum Zitat Offit K, Kohut K, Clagett B, et al.: Cancer genetic testing and assisted reproduction. J Clin Oncol 2006, 24(29):4775–4782.CrossRefPubMed Offit K, Kohut K, Clagett B, et al.: Cancer genetic testing and assisted reproduction. J Clin Oncol 2006, 24(29):4775–4782.CrossRefPubMed
51.
Zurück zum Zitat Staton AD, Kurian AW, Cobb K, Mills MA, Ford JM: Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Fam Cancer 2008, 7(2):179–186.CrossRefPubMed Staton AD, Kurian AW, Cobb K, Mills MA, Ford JM: Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Fam Cancer 2008, 7(2):179–186.CrossRefPubMed
52.
Zurück zum Zitat Menon SJ: Psychotropic medication during pregnancy and lactation. Arch Gynecol Obstet 2008, 277(1):1–13.CrossRefPubMed Menon SJ: Psychotropic medication during pregnancy and lactation. Arch Gynecol Obstet 2008, 277(1):1–13.CrossRefPubMed
53.•
Zurück zum Zitat Rosen A: Third-party reproduction and adoption in cancer patients. J Natl Cancer Inst Monogr 2005, 34:91–93.CrossRefPubMed Rosen A: Third-party reproduction and adoption in cancer patients. J Natl Cancer Inst Monogr 2005, 34:91–93.CrossRefPubMed
Metadaten
Titel
Maintaining Fertility in Young Women with Breast Cancer
verfasst von
Melissa C. Hulvat, MD
Jacqueline S. Jeruss, MD, PhD
Publikationsdatum
01.12.2009
Verlag
Springer US
Erschienen in
Current Treatment Options in Oncology / Ausgabe 5-6/2009
Print ISSN: 1527-2729
Elektronische ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-010-0116-2

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.